Becton Dickinson Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Becton Dickinson wird ein jährliches Gewinn- und Umsatzwachstum von 16.3% bzw. 5.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.5% betragen.
Wichtige Informationen
15.9%
Wachstumsrate der Gewinne
15.1%
EPS-Wachstumsrate
Medical Equipment Gewinnwachstum | 17.5% |
Wachstumsrate der Einnahmen | 5.3% |
Zukünftige Eigenkapitalrendite | 15.5% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 25 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
Sep 13Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy
Aug 06Why We're Not Concerned About Becton, Dickinson and Company's (NYSE:BDX) Share Price
Jul 16An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 36% Undervalued
Jun 27Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?
May 24Becton, Dickinson and Company: Stagnating All Along
May 16Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)
Mar 23Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)
Feb 29Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings
Feb 08Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 03These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Feb 01Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play
Jan 22Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 30Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24
Nov 13Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's
Nov 12Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price
Nov 06With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case
Oct 05Becton, Dickinson Stock Is A Hold, Here's Why
Oct 04Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers
Aug 30We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Aug 13Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Jul 28Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching
Jun 22Becton, Dickinson and Company: Still Not Very Healthy
Jun 20Becton, Dickinson: Business Should Beat H2 2023 Expectations
Jun 08These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well
Apr 22Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?
Mar 20Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)
Mar 05Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use
Feb 21Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test
Feb 08Becton, Dickinson Q1 2023 Earnings Preview
Feb 01Becton, Dickinson declares $0.91 dividend
Jan 24We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt
Jan 09CerTest/Becton, Dickinson's test for monkeypox gets FDA emergency use nod
Jan 09Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
9/30/2026 | 22,481 | 2,647 | 3,465 | 4,888 | 11 |
9/30/2025 | 21,532 | 2,423 | 4,206 | 4,895 | 16 |
9/30/2024 | 20,152 | 2,002 | 3,028 | 4,486 | 16 |
6/30/2024 | 19,828 | 1,459 | 3,221 | 3,944 | N/A |
3/31/2024 | 19,716 | 1,364 | 3,025 | 3,760 | N/A |
12/31/2023 | 19,492 | 1,265 | 2,649 | 3,431 | N/A |
9/30/2023 | 19,372 | 1,470 | 2,115 | 2,989 | N/A |
6/30/2023 | 19,046 | 1,582 | 1,743 | 2,638 | N/A |
3/31/2023 | 18,809 | 1,556 | 1,009 | 1,966 | N/A |
12/31/2022 | 18,738 | 1,486 | 1,361 | 2,359 | N/A |
9/30/2022 | 18,870 | 1,545 | 1,661 | 2,634 | N/A |
6/30/2022 | 18,958 | 1,412 | 1,465 | 2,575 | N/A |
3/31/2022 | 18,924 | 1,430 | 2,041 | 3,141 | N/A |
12/31/2021 | 18,534 | 1,079 | 2,620 | 3,751 | N/A |
9/30/2021 | 19,131 | 1,514 | 3,453 | 4,647 | N/A |
6/30/2021 | 19,066 | 1,486 | 4,222 | 5,177 | N/A |
3/31/2021 | 18,313 | 1,379 | 4,150 | 5,064 | N/A |
12/31/2020 | 18,207 | 1,507 | 3,476 | 4,359 | N/A |
9/30/2020 | 16,074 | 245 | 2,728 | 3,497 | N/A |
6/30/2020 | 16,917 | 786 | 2,474 | 3,429 | N/A |
3/31/2020 | 17,414 | 923 | 2,509 | 3,499 | N/A |
12/31/2019 | 17,355 | 760 | 2,835 | 3,798 | N/A |
9/30/2019 | 17,290 | 1,081 | 2,373 | 3,330 | N/A |
6/30/2019 | 17,108 | 784 | 2,359 | 3,265 | N/A |
3/31/2019 | 17,036 | 926 | 2,009 | 2,875 | N/A |
12/31/2018 | 17,063 | 894 | 1,906 | 2,790 | N/A |
9/30/2018 | 15,983 | 159 | 1,970 | 2,865 | N/A |
6/30/2018 | 14,747 | 621 | 1,837 | 2,685 | N/A |
3/31/2018 | 13,503 | -99 | N/A | 2,527 | N/A |
12/31/2017 | 12,251 | 294 | N/A | 2,555 | N/A |
9/30/2017 | 12,093 | 1,030 | N/A | 2,550 | N/A |
6/30/2017 | 12,158 | 759 | N/A | 2,129 | N/A |
3/31/2017 | 12,321 | 1,314 | N/A | 2,579 | N/A |
12/31/2016 | 12,419 | 1,309 | N/A | 2,411 | N/A |
9/30/2016 | 12,483 | 976 | N/A | 2,559 | N/A |
6/30/2016 | 12,312 | 1,139 | N/A | 2,532 | N/A |
3/31/2016 | 12,234 | 810 | N/A | 2,236 | N/A |
12/31/2015 | 11,217 | 688 | N/A | 1,907 | N/A |
9/30/2015 | 10,282 | 695 | N/A | 1,730 | N/A |
6/30/2015 | 9,410 | 815 | N/A | 1,591 | N/A |
3/31/2015 | 8,448 | 1,079 | N/A | 1,492 | N/A |
12/31/2014 | 8,468 | 1,150 | N/A | 1,677 | N/A |
9/30/2014 | 8,446 | 1,185 | N/A | 1,746 | N/A |
6/30/2014 | 8,345 | 974 | N/A | 1,876 | N/A |
3/31/2014 | 8,239 | 941 | N/A | 1,830 | N/A |
12/31/2013 | 8,169 | 930 | N/A | 1,626 | N/A |
9/30/2013 | 8,054 | 929 | N/A | 1,505 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BDXDas prognostizierte Gewinnwachstum (18% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: BDXDie Erträge des Unternehmens (18% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: BDXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: BDXDie Einnahmen des Unternehmens (5.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).
Hohe Wachstumseinnahmen: BDXDie Einnahmen des Unternehmens (5.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BDXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.5%).